{'fraction_non_alphanumeric': 0.011396011396011397, 'fraction_numerical': 0.0, 'mean_word_length': 5.0085470085470085, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New developments in the field of diffuse large cell lymphoma

Abstract This update will focus on new developments which can impact the understanding and management of patients with DLCL. The latter disorder is mostly derived from B lymphocytes which can be further subdivided into those that originate from the germinal center versus those that arise from non-germinal center areas in the lymph node. The differences between these two types will be discussed. The management of several new entities that relate to DLCL such as ‘double hit lymphoma’ and so called borderline entities will also be featured. New entities such as breast implant associated anaplastic large cell lymphoma will be described.